Intervention not reported
Total studies: 25 RCTs Total participants: 25,583 · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Intervention not reported
HD‐ICS (Direct evidence; 4 RCTs; 1685 participants) · adolescents and adults with uncontrolled asthma, despite being on medium‐dose ICS Interventions: HD‐ICS, LD‐ICS/LABA, MD‐ICS/LAMA,…
1 finding from 1 review
Mortality (all‐cause) · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes mortality (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Any COPD exacerbation that requires short‐burst oral corticosteroids or antibiotics, or both · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes any COPD exacerbation that requires short‐burst oral corticosteroids… compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Pneumonia · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes pneumonia compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Quality of life · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Hospital admissions · patients with chronic obstructive pulmonary disease
It is very uncertain whether once‐daily ICS/LABA combined inhalers changes hospital admissions (all‐cause) compared with once‐daily LAMA (very low certainty).
1 finding from 1 review
Exacerbations leading to intubation · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Physical activity measure (e.g. 6MWT) · patients with chronic obstructive pulmonary disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Moderate to severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Moderate to severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in moderate to severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Severe exacerbations: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Severe exacerbations: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in severe exacerbations: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Pneumonia: high‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS probably leads to higher pneumonia: high‐risk population compared with LAMA (moderate certainty).
1 finding from 1 review
Pneumonia: low‐risk population · chronic obstructive pulmonary disease with predicted FEV1 of less than 80%
LABA/ICS showed no clear difference in pneumonia: low‐risk population compared with LAMA (low certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring oral corticosteroids 48 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring oral corticosteroids 48 weeks (moderate certainty).
1 finding from 1 review
Intervention not reported
Quality of life (AQLQ) · adults with asthma
1 finding from 1 review
Intervention not reported
Serious adverse events 49 weeks · adults with asthma
The intervention showed no clear difference in serious adverse events 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Exacerbations requiring hospital admission 49 weeks · adults with asthma
The intervention showed no clear difference in exacerbations requiring hospital admission 49 weeks (low certainty).
1 finding from 1 review
Intervention not reported
Lung function (change in trough FEV1 L) · adults with asthma
1 finding from 1 review